Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary ...
Feb 25 (Reuters) - GSK has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking ...
The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.
"We are excited to establish the agreement with GSK, a global biopharma company. It reflects the growing recognition of our R&D capabilities. This agreement will solidify a robust foundation for ...
35Pharma's lead development programme is HS235, an activin receptor-targeting fusion protein that has completed phase 1 ...
GSK (GSK) stock is in focus as the company inks a drug licensing deal worth up to $1B with China's Frontier Biotechnologies for siRNA treatments. Read more here.
GSK acquires 35Pharma for $950M. The primary focus is HS235, a selective PH drug reducing bleeding risk with metabolic ...
GSK plc (NSE: GSK) on Wednesday agreed to acquire 35Pharma Inc. for $950 million. 35Pharma is a Canada-based, private, ...
The 35Pharma acquisition comes as GSK looks to stock up its pipeline amid the looming patent expiries soon to impact its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results